Abiopharma

🔍 STEELE GLENN JR MD PHD (Executive)

Company: PTC THERAPEUTICS, INC. (PTCT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 12,000 shares of Common Stock at $30.86 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,500.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,000 shares of Common Stock at $76.35 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,500.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,000 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 22,500.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12,000 shares of Stock Option (Right to Buy) at $30.86 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2026-01-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 3,475 shares of Stock Option (Right to Buy) at $76.74 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 3,475.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 8, 2025.
• F2: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
• F3: Currently exercisable.
• F4: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.